Kiora Pharmaceuticals Inc expected to post a loss of 76 cents a share - Earnings Preview

Kiora Pharmaceuticals

06/11/2024 14:29

* Kiora Pharmaceuticals Inc  KPRX.OQ   KPRX.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
7 (estimated) for the period ending September 30 2024
    * The Encinitas California-based  company is expected to
report
revenue of $7 thousand, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Kiora Pharmaceuticals
Inc is
for a loss of 76 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiora
Pharmaceuticals Inc is 27.00​, above​ its last closing price
of $3.52. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.87       -0.86      -0.53     Beat    38.1
 Mar. 31 2024  -0.59       -0.59      3.42      Beat    675.8
 Dec. 31 2023  -3.69       -3.77      -4.23     Missed  -12.3​
 Sep. 30 2023  -3.09       -3.18      -8.01     Missed  -151.9
 ​​Jan.        -6.63       -9.59      -7.11     Beat    25.9
 1 0001                                                 
 Mar. 31 2023  -15.41                 -9.00             40.7​
 Jan. 1 0001   -20.04      -22.14     -15.81    Beat    28.6
 Sep. 30 2022  -33.12      -34.51     -54.30    Missed  -57.3
 This summary was machine generated November 6 at 14:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)